LinkedIn Profile

Access CARsgen Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
private:carsgen 10048828 Nov 18th, 2019 12:00AM CARsgen Therapeutics 1.1K 27.00 Open Biotechnology Nov 18th, 2019 03:57PM Nov 18th, 2019 03:57PM CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics. Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma, and CAR-Claudin18.2-T trial for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs with a humanized CAR-CD19-T trial for leukemia, and a fully human CAR-BCMA-T trial for multiple myeloma. CARsgen intends to submit 5 INDs to the NMPA(National Medical Products Administration, China) and 2 INDs to the FDA in 2019, speeding up our commitment to delivering cures to cancer patients worldwide. Open Immunotherapy, solid tumor, CAR-T, oncology Open 1F, Building 2, No.466, Yindu Rd Shanghai Shanghai CN 200231
private:carsgen 10048828 Nov 17th, 2019 12:00AM CARsgen Therapeutics 1.1K 27.00 Open Biotechnology Nov 17th, 2019 04:22PM Nov 17th, 2019 04:22PM CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics. Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma, and CAR-Claudin18.2-T trial for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs with a humanized CAR-CD19-T trial for leukemia, and a fully human CAR-BCMA-T trial for multiple myeloma. CARsgen intends to submit 5 INDs to the NMPA(National Medical Products Administration, China) and 2 INDs to the FDA in 2019, speeding up our commitment to delivering cures to cancer patients worldwide. Open Immunotherapy, solid tumor, CAR-T, oncology Open 1F, Building 2, No.466, Yindu Rd Shanghai Shanghai CN 200231
private:carsgen 10048828 Nov 16th, 2019 12:00AM CARsgen Therapeutics 1.1K 27.00 Open Biotechnology Nov 16th, 2019 04:17PM Nov 16th, 2019 04:17PM CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics. Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma, and CAR-Claudin18.2-T trial for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs with a humanized CAR-CD19-T trial for leukemia, and a fully human CAR-BCMA-T trial for multiple myeloma. CARsgen intends to submit 5 INDs to the NMPA(National Medical Products Administration, China) and 2 INDs to the FDA in 2019, speeding up our commitment to delivering cures to cancer patients worldwide. Open Immunotherapy, solid tumor, CAR-T, oncology Open 1F, Building 2, No.466, Yindu Rd Shanghai Shanghai CN 200231
private:carsgen 10048828 Nov 15th, 2019 12:00AM CARsgen Therapeutics 1.1K 27.00 Open Biotechnology Nov 15th, 2019 12:53PM Nov 15th, 2019 12:53PM CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics. Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma, and CAR-Claudin18.2-T trial for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs with a humanized CAR-CD19-T trial for leukemia, and a fully human CAR-BCMA-T trial for multiple myeloma. CARsgen intends to submit 5 INDs to the NMPA(National Medical Products Administration, China) and 2 INDs to the FDA in 2019, speeding up our commitment to delivering cures to cancer patients worldwide. Open Immunotherapy, solid tumor, CAR-T, oncology Open 1F, Building 2, No.466, Yindu Rd Shanghai Shanghai CN 200231
private:carsgen 10048828 Nov 13th, 2019 12:00AM CARsgen Therapeutics 1.1K 27.00 Open Biotechnology Nov 13th, 2019 01:18PM Nov 13th, 2019 01:18PM CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics. Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma, and CAR-Claudin18.2-T trial for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs with a humanized CAR-CD19-T trial for leukemia, and a fully human CAR-BCMA-T trial for multiple myeloma. CARsgen intends to submit 5 INDs to the NMPA(National Medical Products Administration, China) and 2 INDs to the FDA in 2019, speeding up our commitment to delivering cures to cancer patients worldwide. Open Immunotherapy, solid tumor, CAR-T, oncology Open 1F, Building 2, No.466, Yindu Rd Shanghai Shanghai CN 200231
private:carsgen 10048828 Nov 12th, 2019 12:00AM CARsgen Therapeutics 1.1K 27.00 Open Biotechnology Nov 12th, 2019 03:00PM Nov 12th, 2019 03:00PM CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics. Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma, and CAR-Claudin18.2-T trial for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs with a humanized CAR-CD19-T trial for leukemia, and a fully human CAR-BCMA-T trial for multiple myeloma. CARsgen intends to submit 5 INDs to the NMPA(National Medical Products Administration, China) and 2 INDs to the FDA in 2019, speeding up our commitment to delivering cures to cancer patients worldwide. Open Immunotherapy, solid tumor, CAR-T, oncology Open 1F, Building 2, No.466, Yindu Rd Shanghai Shanghai CN 200231
private:carsgen 10048828 Nov 11th, 2019 12:00AM CARsgen Therapeutics 1.1K 27.00 Open Biotechnology Nov 11th, 2019 02:58PM Nov 11th, 2019 02:58PM CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics. Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma, and CAR-Claudin18.2-T trial for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs with a humanized CAR-CD19-T trial for leukemia, and a fully human CAR-BCMA-T trial for multiple myeloma. CARsgen intends to submit 5 INDs to the NMPA(National Medical Products Administration, China) and 2 INDs to the FDA in 2019, speeding up our commitment to delivering cures to cancer patients worldwide. Open Immunotherapy, solid tumor, CAR-T, oncology Open 1F, Building 2, No.466, Yindu Rd Shanghai Shanghai CN 200231
private:carsgen 10048828 Nov 10th, 2019 12:00AM CARsgen Therapeutics 1.1K 27.00 Open Biotechnology Nov 10th, 2019 06:05PM Nov 10th, 2019 06:05PM CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics. Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma, and CAR-Claudin18.2-T trial for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs with a humanized CAR-CD19-T trial for leukemia, and a fully human CAR-BCMA-T trial for multiple myeloma. CARsgen intends to submit 5 INDs to the NMPA(National Medical Products Administration, China) and 2 INDs to the FDA in 2019, speeding up our commitment to delivering cures to cancer patients worldwide. Open Immunotherapy, solid tumor, CAR-T, oncology Open 1F, Building 2, No.466, Yindu Rd Shanghai Shanghai CN 200231
private:carsgen 10048828 Nov 9th, 2019 12:00AM CARsgen Therapeutics 1.1K 27.00 Open Biotechnology Nov 9th, 2019 05:32PM Nov 9th, 2019 05:32PM CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics. Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma, and CAR-Claudin18.2-T trial for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs with a humanized CAR-CD19-T trial for leukemia, and a fully human CAR-BCMA-T trial for multiple myeloma. CARsgen intends to submit 5 INDs to the NMPA(National Medical Products Administration, China) and 2 INDs to the FDA in 2019, speeding up our commitment to delivering cures to cancer patients worldwide. Open Immunotherapy, solid tumor, CAR-T, oncology Open 1F, Building 2, No.466, Yindu Rd Shanghai Shanghai CN 200231
private:carsgen 10048828 Nov 8th, 2019 12:00AM CARsgen Therapeutics 1.1K 27.00 Open Biotechnology Nov 8th, 2019 02:43PM Nov 8th, 2019 02:43PM CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics. Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma, and CAR-Claudin18.2-T trial for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs with a humanized CAR-CD19-T trial for leukemia, and a fully human CAR-BCMA-T trial for multiple myeloma. CARsgen intends to submit 5 INDs to the NMPA(National Medical Products Administration, China) and 2 INDs to the FDA in 2019, speeding up our commitment to delivering cures to cancer patients worldwide. Open Immunotherapy, solid tumor, CAR-T, oncology Open 1F, Building 2, No.466, Yindu Rd Shanghai Shanghai CN 200231

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.